Table 3:

Summary of the key findings of the current study and previous comparative studies. “HL” = higher in HL. “Non-HL” = higher in non-HL. ns = no statistical significant difference between HL and non-HL. Empty cell = not reported.

	The current study a	Moh et al (2018) a	Doiron et al (2016)	Peters et al (2011)
N	223	150	359	214
% with HL	12.5%	27.3%	12.2%	16.8%
Demographics:
Age	HL (older)	HL (older)	HL (older)	HL (older)
Sex	ns	ns
Race	ns	ns
Pelvic symptoms:
Urologic pain intensity	ns	non-HL	HL
Urinary frequency		ns	HL	HL
Urgency		ns	ns
Nocturia	HL	HL	HL	HL
Symptom duration	ns		ns	Non-HL
ICSI	HL	ns	HL	ns
ICPI	HL	ns	ns	ns
Painful urgency	HL
Genital pain	ns
Pelvic floor tenderness	ns
Systemic presentation:
Non-urologic pain intensity	Non-HL	ns (trending non-HL)
Irritable bowel syndrome	ns	Non-HL	ns	ns
Fibromyalgia	ns	ns		Non-HL
Chronic fatigue syndrome	ns	ns		ns
Migraine headache	Non-HL	ns		Non-HL
Temporomandibular joint disorder	ns			Non-HL
Vulvodynia	ns	ns		ns
No. of COPC	Non-HL
Anxiety	Non-HL	Non-HL		ns
Depression	ns	ns		ns
Perceived tress	Non-HL
Catastrophizing	Non-HL
Widespread pain	Non-HL	ns
Fibromyalgia-ness	Non-HL
Quality of life:	ns

^aThe participants in these two studies did not overlap.